SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Core Viewpoint - Bolt Biotherapeutics, Inc. is facing a federal securities class action due to allegations of misleading statements regarding the effectiveness of its lead asset, BDC-1001, and the overall prospects of its product pipeline [3][6]. Company Overview - Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) has been under scrutiny for allegedly overstating the effectiveness of its lead product, BDC-1001, which is now deemed unlikely to meet its success criteria [3]. - The company announced on May 14, 2024, that it would cease further development of BDC-1001 and reduce its workforce by approximately 50% [10]. Financial Impact - Following the announcement regarding the cessation of BDC-1001's development, Bolt's stock price fell by $0.49 per share, representing a decline of over 37.12%, closing at $0.83 per share on May 15, 2024 [7][10]. Legal Proceedings - A federal securities class action has been filed against Bolt, with a deadline of September 3, 2024, for investors to seek the role of lead plaintiff [6]. - The lead plaintiff is typically the investor with the largest financial interest in the relief sought and is responsible for directing the litigation on behalf of the class [4].